DURHAM, N.C.--(BUSINESS WIRE)--Inspire Pharmaceuticals, Inc. (NASDAQ:ISPH) announced today that a presentation of its Phase 2 clinical trial data on epinastine nasal spray for the treatment of allergic rhinitis will be given during the American College of Allergy, Asthma & Immunology (ACAAI) 2007 Annual Meeting on November 8 – 11, 2007 in Dallas. The oral presentation by Paul H. Ratner, M.D., M.B.A., will occur on November 11th at 1:00 p.m. and is based on data contained in the abstract, “Epinastine Nasal Spray is Effective and Well Tolerated for the Treatment of Seasonal Allergic Rhinitis.”
